FuturHealth Review
Best for: readers who want both brand-name and compounded GLP-1 options on one platform with registered-dietitian nutrition coaching, AND are willing to read the data-breach litigation disclosure before signing up
FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added Q2 2026) plus clinician-discretionary compounded GLP-1/GIP combinations, dispensed through US-based licensed pharmacies. The platform layers digital coaching and registered-dietitian nutrition guidance on top of the medication.
Medium confidence · Last verified 2026-05-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
FuturHealth is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
FuturHealth prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Preliminary | compounded | $199 |
✓ Pros
- •LegitScript Certified and HITRUST Certified — two independently verifiable telehealth/health-data trust marks
- •Brand-name injection + oral pill GLP-1s on one platform: Wegovy injection, Wegovy oral pill, Zepbound, Mounjaro, Ozempic, Foundayo (orforglipron oral, added Q2 2026), plus clinician-discretionary compounded options
- •First-mover on dispensing Foundayo (orforglipron, FDA-approved April 2026) — earliest direct-to-consumer access to the new oral non-peptide GLP-1
- •Bundled registered-dietitian nutrition guidance — most pure-Rx telehealths leave nutrition support to the patient
✗ Cons
- •ACTIVE LITIGATION: Wilson v. FuturHealth Inc., U.S. District Court Southern District of California, Case No. 3:2025cv00157, alleging unauthorized access to G-Plans subscriber data on/before October 16, 2024 and asserting CCPA, medical-confidentiality, and negligence claims. Material disclosure for any reader signing up.
- •BBB complaint pattern: multiple consumer reports of recurring unauthorized charges (e.g. $396/month) without medication being received — verify cancellation flow before subscribing
- •Pharmacy partners are described as 'licensed, U.S.-based pharmacies' but no specific 503A/503B partners are publicly named
- •Pricing is not displayed on the public landing page — visible only after qualification questionnaire/portal login
- •Clinical platform is white-labeled on top of SteadyMD and OpenLoop infrastructure — FuturHealth is the front-end brand, not the first-party prescribing entity
Ready to start with FuturHealth?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our FuturHealth review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to FuturHealth
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with FuturHealth?
Starting at $199/month. See current pricing and start your free consultation.